NASDAQ: TNXP
HQ: Chatham, NJ
$140M of Cash
As of 9/30/22
investor.relations@
tonixpharma.com
MANAGEMENT TEAM
Seth Lederman, MD
Co-Founder, CEO & Chairman
Gregory Sullivan, MD
Chief Medical Officer
Bradley Saenger, CPA
Chief Financial Officer
What We Do
Tonix is committed to improving population health by inventing and developing innovative therapies and vaccines, through broad in- house capabilities and creative collaborations, to help address important unmet needs.
Leveraging the expertise of the Company's leaders, Tonix's strategy includes:
- Development of a diverse yet curated portfolio, including small molecule drugs and biologics, across a range of therapeutic areas
- Investment in domestic, in-house, R&D and manufacturing to accelerate development timelines and improve the ability to respond to pandemics
- Partnering strategically with other biotech companies, world-class academic and non-profit research organizations to bring innovative therapeutics to market faster
Therapeutic Areas
Jessica Morris
Chief Operating Officer
MAIN U.S. OFFICES
New Jersey Office
(Corporate Headquarters)
26 Main Street - Ste 101
Chatham, NJ 07928
New York Office
509 Madison Ave. - Ste 1608 New York, NY 10022
Research and Development Center (RDC)
431 Aviation Way Frederick, MD 21701
Advanced Development Center (ADC)
259 Samuel Barnet Blvd
New Bedford Business Park
North Dartmouth, MA 02745
www.tonixpharma.com
@TonixPharma
Central Nervous
System
Immunology
Infectious
Disease
Rare
Disease
Tonix is dedicated to finding treatments for difficult-to-treat, widely occurring, chronic disorders of the central nervous system including pain, neurologic, psychiatric and addiction conditions, using non-opioid,non-addictive therapies.
Tonix is advancing scientific programs that focus on therapeutics to prevent organ transplant rejection, to manage autoimmune conditions, and to improve responses to immunotherapy in certain cancers.
Tonix is targeting pathogenic infections, including monkeypox and smallpox for biodefense, as well as the ongoing COVID-19 pandemic. Through its live virus vaccine platform and in-house capabilities, Tonix strives to be prepared for future pandemics.
Tonix is developing novel therapies for patients with rare diseases, including those caused by genetic disorders which are characterized by complex symptoms and for which no drug is approved.
Development Pipeline: Key Product Candidates
Using our integrated development engine, we advance innovative programs into the clinic
Central Nervous System
TNX-102SL Fibromyalgia (FM) Confirmatory Phase 3: initiated 2Q 2022 Interim analysis results: expected 2Q 2023
TNX-102SL Posttraumatic Stress Disorder (PTSD)
Phase 2 start: targeting 2Q 2023
TNX-102 SL Long COVID Phase 2: initiated 3Q 2022
Interim analysis results: expected 3Q 2023
TNX-601ER Major Depressive Disorder
Phase 2: targeting 1Q 2023
TNX-1300 Cocaine Intoxication/Overdose
Phase 2 start: targeting 1Q 2023
TNX-1900 Chronic Migraine
Phase 2 start: targeting 1Q 2023
Status | Small Molecule | Biologic / | Monoclonal |
Small Peptide | Antibody (mAb) | ||
Mid-Phase 3 | + |
Phase 2 ready | + |
Phase 2 | + |
Phase 2 ready | + |
Mid-Phase 2 | + |
Phase 2 ready | + |
Immunology
Status | Small Molecule | Biologic / | Monoclonal | |
Small Peptide | Antibody (mAb) | |||
TNX-1500 Organ Transplant | + | |||
Rejection/Autoimmune Disorders | Preclinical | |||
Phase 1 start: targeting 1H 2023 | ||||
TNX-1700 Gastric and Colorectal Cancers | Preclinical | + |
Infectious Disease
TNX-801 Smallpox and Monkeypox Vaccine Phase 1 start: targeting 2H 2023
TNX-1850 COVID-19 Vaccine
Status | Small Molecule | Biologic / | Monoclonal |
Small Peptide | Antibody (mAb) | ||
Preclinical | + | ||
Preclinical | + | ||
Rare Disease
Status | Small Molecule | Biologic / | Monoclonal | |
Small Peptide | Antibody (mAb) | |||
TNX-2900 Prader-Willi Syndrome | Preclinical | + | ||
Orphan Drug Designation | ||||
*All of Tonix's product candidates are investigational new drugs or biologics and have not been approved for any indication. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. We cannot predict whether the global COVID-19 pandemic will impact the timing of these milestones.
Our Facilities
We are building out our internal R&D and manufacturing capabilities in the US
Research and Development Center | Advanced Development Center | Commercial Manufacturing Center | ||||||
(RDC) | (ADC) | (CMC) | ||||||
Function | Accelerated development of vaccines and | Development and clinical scale | Phase 3 and Commercial scale | |||||
antiviral drugs for COVID-19, its variants | ||||||||
manufacturing of biologics | manufacturing of biologics | |||||||
and other infectious diseases | ||||||||
Description | ~48,000 square feet, BSL-2 with some | ~45,000 square feet, BSL-2 | ~44 acre green field site, planned BSL-2 | |||||
areas designated BSL-3 | ||||||||
Status | Operational | Operational | Planning for site enabling work in 2023 | |||||
Location | Frederick, Maryland | North Dartmouth, Massachusetts | Hamilton, Montana | |||||
© 2022 Tonix Pharmaceuticals Holding Corp.
All rights reserved.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Tonix Pharmaceuticals Holding Corp. published this content on 04 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 January 2023 14:07:03 UTC.